Promis Neurosciences (PMN) Competitors $0.46 +0.02 (+3.35%) As of 07/3/2025 03:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMN vs. ICCC, VHAQ, CLSD, PYRGF, ASRT, ACHL, PDSB, STRO, UNCY, and RPTXShould you be buying Promis Neurosciences stock or one of its competitors? The main competitors of Promis Neurosciences include ImmuCell (ICCC), Viveon Health Acquisition (VHAQ), Clearside Biomedical (CLSD), PyroGenesis Canada (PYRGF), Assertio (ASRT), Achilles Therapeutics (ACHL), PDS Biotechnology (PDSB), Sutro Biopharma (STRO), Unicycive Therapeutics (UNCY), and Repare Therapeutics (RPTX). These companies are all part of the "pharmaceutical products" industry. Promis Neurosciences vs. Its Competitors ImmuCell Viveon Health Acquisition Clearside Biomedical PyroGenesis Canada Assertio Achilles Therapeutics PDS Biotechnology Sutro Biopharma Unicycive Therapeutics Repare Therapeutics ImmuCell (NASDAQ:ICCC) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment. Does the media refer more to ICCC or PMN? In the previous week, ImmuCell had 1 more articles in the media than Promis Neurosciences. MarketBeat recorded 1 mentions for ImmuCell and 0 mentions for Promis Neurosciences. ImmuCell's average media sentiment score of 1.11 beat Promis Neurosciences' score of 0.00 indicating that ImmuCell is being referred to more favorably in the media. Company Overall Sentiment ImmuCell Positive Promis Neurosciences Neutral Do insiders & institutionals have more ownership in ICCC or PMN? 13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 6.6% of ImmuCell shares are owned by company insiders. Comparatively, 6.1% of Promis Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, ICCC or PMN? ImmuCell has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Promis Neurosciences has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500. Is ICCC or PMN more profitable? Promis Neurosciences has a net margin of 0.00% compared to ImmuCell's net margin of -1.00%. ImmuCell's return on equity of -1.02% beat Promis Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets ImmuCell-1.00% -1.02% -0.61% Promis Neurosciences N/A -186.19%-98.56% Which has preferable earnings & valuation, ICCC or PMN? Promis Neurosciences has lower revenue, but higher earnings than ImmuCell. ImmuCell is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuCell$26.49M2.29-$2.16M-$0.07-95.93Promis NeurosciencesN/AN/A$2.78M-$0.05-9.26 Do analysts rate ICCC or PMN? Promis Neurosciences has a consensus price target of $4.50, indicating a potential upside of 871.92%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts plainly believe Promis Neurosciences is more favorable than ImmuCell.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Promis Neurosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPromis Neurosciences beats ImmuCell on 8 of the 15 factors compared between the two stocks. Get Promis Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMN vs. The Competition Export to ExcelMetricPromis NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.14M$2.88B$5.50B$9.02BDividend YieldN/A2.43%5.38%4.10%P/E Ratio-9.2621.5627.6020.30Price / SalesN/A174.49369.54104.24Price / CashN/A41.9536.6357.47Price / Book0.937.518.055.68Net Income$2.78M-$55.05M$3.18B$249.13M7 Day Performance-3.58%4.61%2.82%3.30%1 Month Performance-8.10%4.89%3.69%5.20%1 Year Performance-71.24%5.84%35.41%21.37% Promis Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMNPromis Neurosciences3.407 of 5 stars$0.46+3.3%$4.50+871.9%-71.2%$15.14MN/A-9.265Gap UpHigh Trading VolumeICCCImmuCell0.3208 of 5 stars$6.62-4.9%N/A+56.9%$62.90M$26.49M-94.5670News CoverageGap UpVHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumeCLSDClearside Biomedical1.4545 of 5 stars$0.79-0.9%$4.75+499.1%-34.2%$62.17M$1.66M-1.9330PYRGFPyroGenesis Canada0.0922 of 5 stars$0.33+0.9%N/A-36.9%$62.17M$9.14M-5.5590ASRTAssertio1.7671 of 5 stars$0.64+0.1%$2.75+328.5%-49.9%$61.42M$124.96M-2.0120Gap DownACHLAchilles TherapeuticsN/A$1.48flatN/AN/A$60.83MN/A-0.90250PDSBPDS Biotechnology2.4138 of 5 stars$1.22-8.3%$9.00+637.7%-55.6%$60.79MN/A-1.3020News CoverageAnalyst ForecastSTROSutro Biopharma3.3574 of 5 stars$0.68-4.7%$6.11+799.2%-73.4%$60.30M$62.04M-0.23240UNCYUnicycive Therapeutics3.1844 of 5 stars$4.90+2.7%$60.00+1,124.5%-5.4%$60.30M$680K-0.969High Trading VolumeRPTXRepare Therapeutics2.1456 of 5 stars$1.42+2.2%$4.50+216.9%-56.9%$59.62M$53.48M-0.47180News CoveragePositive News Related Companies and Tools Related Companies ImmuCell Alternatives Viveon Health Acquisition Alternatives Clearside Biomedical Alternatives PyroGenesis Canada Alternatives Assertio Alternatives Achilles Therapeutics Alternatives PDS Biotechnology Alternatives Sutro Biopharma Alternatives Unicycive Therapeutics Alternatives Repare Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMN) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Promis Neurosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Promis Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PMN Stock Alerts